HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Calcibiotic Root Canal Sealer

Also Known As:
CRCS
Networked: 2411 relevant articles (68 outcomes, 305 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Kang, Gyeong Hoon: 37 articles (03/2022 - 12/2009)
2. Goel, Ajay: 29 articles (01/2020 - 01/2004)
3. Bae, Jeong Mo: 26 articles (03/2022 - 07/2011)
4. Boland, C Richard: 25 articles (11/2019 - 01/2004)
5. Cho, Nam-Yun: 24 articles (03/2022 - 07/2011)
6. Kim, Jung Ho: 24 articles (03/2022 - 12/2009)
7. Suzuki, Hiromu: 20 articles (06/2022 - 07/2005)
8. Kloor, Matthias: 19 articles (01/2022 - 07/2007)
9. Nagasaka, Takeshi: 19 articles (04/2020 - 11/2003)
10. Meijer, Gerrit A: 18 articles (02/2021 - 12/2007)

Related Diseases

1. Neoplasms (Cancer)
08/01/2021 - "Compared with para-cancer tissues, there was a marked decrease of DAB2IP expression in surgically excised CRCs. "
06/01/2011 - "Moreover, our results demonstrated that molecular screening and subsequent instrumental surveillance are very effective in identifying CRCs at earlier stages and reducing the number of deaths from secondary cancers in HNPCC patients."
01/01/2009 - "Two RCTs from the United Kingdom and Denmark showed significant reduction in CRC mortality using unrehydrated gFOBT biennially Relative risk reductions of 13% (UK trial) and 16% (Danish trial); absolute difference of 0.1% (UK trial) and 0.2% (Danish trial).No significant reduction in overall mortalityInterval cancers (CRC that develop in the intervals between routine screening) UNITED KINGDOM TRIAL: 236 CRCs detected by positive test, 236 interval CRCs after negative testDANISH TRIAL: 120 CRCs detected by positive test, 146 interval CRCs after negative testUnrehydrated gFOBT has low sensitivity for CRC detection (45% in the UK trial and 54% in the Danish trial). "
01/01/2018 - "The expression of Immunoscore-like metagenes was statistically significantly associated with improved outcome in non-MSI tumors displaying low levels of both CTLs and immune checkpoints (ICKs; CMS2 and CMS3; hazard ratio [HR] = 0.63, 95% confidence interval [CI] = 0.43 to 0.92, P = .02; and HR = 0.55, 95% CI = 0.34 to 0.90, P = .02, respectively), but clearly had no prognostic relevance in CRCs displaying higher levels of CTLs and ICKs (CMS1 and CMS4; HR = 0.46, 95% CI = 0.10 to 2.10, P = .32; and HR = 1.13, 95% CI = 0.79 to 1.63, P = .50, respectively), including MSI tumors. "
01/01/2014 - "CRCs with MYC over-expression demonstrated improved 5-year survival (93.2% vs. 57.3%), with the effect significantly modulated by the dominant effect of tumor stage, age at diagnosis and lymphovascular space invasion status on survival. "
2. Colorectal Neoplasms (Colorectal Cancer)
3. Adenoma (Adenomas)
4. Microsatellite Instability
5. Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer)

Related Drugs and Biologics

1. ErbB Receptors (EGF Receptor)
2. Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
3. Proteins (Proteins, Gene)
4. Cetuximab (Erbitux)
5. Biomarkers (Surrogate Marker)
6. DNA (Deoxyribonucleic Acid)
7. Messenger RNA (mRNA)
8. Fluorouracil (Carac)
9. Oxaliplatin (Eloxatin)
10. Thymidylate Synthase

Related Therapies and Procedures

1. Therapeutics
2. Immunotherapy
3. Drug Therapy (Chemotherapy)
4. Adjuvant Chemotherapy
5. Chemoradiotherapy